论文部分内容阅读
目的研究微小RNA-29b(miRNA-29b)在肺腺癌中的表达及其临床意义。方法采用荧光定量RT-PCR法检测82例肺腺癌组织及其癌旁正常肺组织中miRNA-29b的表达,分析其与临床病理学特征的关系。结果肺腺癌组织中miRNA-29b表达高于癌旁正常肺组织(P<0.01)。肺腺癌组织中miRNA-29b表达与患者肿瘤组织分化程度、临床分期、淋巴结转移状态以及总生存期密切相关(P<0.01),而与性别、年龄和吸烟史无明显相关(P>0.05)。肿瘤的临床分期、淋巴结转移状态以及miRNA-29b表达水平均为判断肺腺癌患者预后的独立因素(P<0.01)。结论 miRNA-29b表达下调参与肺腺癌的发生、发展过程,有望成为临床肺腺癌患者早期诊断和预后评估的分子学标志物。
Objective To study the expression of microRNA-29b (miRNA-29b) in human lung adenocarcinoma and its clinical significance. Methods The expression of miRNA-29b in 82 lung adenocarcinoma tissues and adjacent normal lung tissues was detected by real-time fluorescence quantitative RT-PCR. The relationship between miRNA-29b and clinical pathological features was analyzed. Results The expression of miRNA-29b in lung adenocarcinoma was higher than that in normal lung tissue (P <0.01). The expression of miRNA-29b in lung adenocarcinoma was closely related to the degree of tumor differentiation, clinical stage, lymph node metastasis and overall survival (P <0.01), but not to gender, age and smoking history (P> 0.05) . The clinical stage, lymph node metastasis status and miRNA-29b expression level were independent prognostic factors for lung adenocarcinoma (P <0.01). Conclusion The down-regulation of miRNA-29b expression in lung adenocarcinoma may play an important role in the early diagnosis and prognosis evaluation of lung adenocarcinoma.